These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

320 related items for PubMed ID: 23486550

  • 1. Quadrivalent human papillomavirus vaccine effectiveness: a Swedish national cohort study.
    Leval A, Herweijer E, Ploner A, Eloranta S, Fridman Simard J, Dillner J, Young C, Netterlid E, Sparén P, Arnheim-Dahlström L.
    J Natl Cancer Inst; 2013 Apr 03; 105(7):469-74. PubMed ID: 23486550
    [Abstract] [Full Text] [Related]

  • 2. Association of varying number of doses of quadrivalent human papillomavirus vaccine with incidence of condyloma.
    Herweijer E, Leval A, Ploner A, Eloranta S, Simard JF, Dillner J, Netterlid E, Sparén P, Arnheim-Dahlström L.
    JAMA; 2014 Feb 12; 311(6):597-603. PubMed ID: 24519299
    [Abstract] [Full Text] [Related]

  • 3. Human papillomavirus vaccines effectiveness to prevent genital warts: A population-based study using health system integrated databases, 2009-2017.
    Muñoz-Quiles C, López-Lacort M, Díez-Domingo J, Rodrigo-Casares V, Orrico-Sánchez A.
    Vaccine; 2022 Jan 21; 40(2):316-324. PubMed ID: 34865874
    [Abstract] [Full Text] [Related]

  • 4. Timing of two versus three doses of quadrivalent HPV vaccine and associated effectiveness against condyloma in Sweden: a nationwide cohort study.
    Lamb F, Herweijer E, Ploner A, Uhnoo I, Sundström K, Sparén P, Arnheim-Dahlström L.
    BMJ Open; 2017 Jun 08; 7(6):e015021. PubMed ID: 28600369
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Substantially reduced incidence of genital warts in women and men six years after HPV vaccine availability in Sweden.
    Herweijer E, Ploner A, Sparén P.
    Vaccine; 2018 Apr 05; 36(15):1917-1920. PubMed ID: 29523448
    [Abstract] [Full Text] [Related]

  • 10. Incidence of genital warts in Sweden before and after quadrivalent human papillomavirus vaccine availability.
    Leval A, Herweijer E, Arnheim-Dahlström L, Walum H, Frans E, Sparén P, Simard JF.
    J Infect Dis; 2012 Sep 15; 206(6):860-6. PubMed ID: 22815381
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. The impact of HPV multi-cohort vaccination: Real-world evidence of faster control of HPV-related morbidity.
    Orumaa M, Kjaer SK, Dehlendorff C, Munk C, Olsen AO, Hansen BT, Campbell S, Nygård M.
    Vaccine; 2020 Feb 05; 38(6):1345-1351. PubMed ID: 31917039
    [Abstract] [Full Text] [Related]

  • 13. The quadrivalent HPV vaccine is protective against genital warts: a meta-analysis.
    Lukács A, Máté Z, Farkas N, Mikó A, Tenk J, Hegyi P, Németh B, Czumbel LM, Wuttapon S, Kiss I, Gyöngyi Z, Varga G, Rumbus Z, Szabó A.
    BMC Public Health; 2020 May 28; 20(1):691. PubMed ID: 32460747
    [Abstract] [Full Text] [Related]

  • 14. Population-level impact and herd effects following the introduction of human papillomavirus vaccination programmes: updated systematic review and meta-analysis.
    Drolet M, Bénard É, Pérez N, Brisson M, HPV Vaccination Impact Study Group.
    Lancet; 2019 Aug 10; 394(10197):497-509. PubMed ID: 31255301
    [Abstract] [Full Text] [Related]

  • 15. Strongly decreased risk of genital warts after vaccination against human papillomavirus: nationwide follow-up of vaccinated and unvaccinated girls in Denmark.
    Blomberg M, Dehlendorff C, Munk C, Kjaer SK.
    Clin Infect Dis; 2013 Oct 10; 57(7):929-34. PubMed ID: 23804192
    [Abstract] [Full Text] [Related]

  • 16. Quadrivalent HPV vaccine effectiveness against anogenital warts: A registry-based study of 2,2 million individuals.
    Nygård S, Nygård M, Orumaa M, Hansen BT.
    Vaccine; 2023 Aug 23; 41(37):5469-5476. PubMed ID: 37516572
    [Abstract] [Full Text] [Related]

  • 17. Early Evidence of the Effectiveness of the Human Papillomavirus Vaccination Program Against Anogenital Warts in Manitoba, Canada: A Registry Cohort Study.
    Willows K, Bozat-Emre S, Righolt CH, Kliewer EV, Mahmud SM.
    Sex Transm Dis; 2018 Apr 23; 45(4):254-259. PubMed ID: 29465699
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Quadrivalent human papillomavirus (types 6, 11, 16, 18) recombinant vaccine (Gardasil®): a review of its use in the prevention of premalignant genital lesions, genital cancer and genital warts in women.
    McCormack PL, Joura EA.
    Drugs; 2010 Dec 24; 70(18):2449-74. PubMed ID: 21142263
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 16.